Spinal Cord Stimulators for Pain After SCI: The Evidence, the Companies & Why They're So Hard to Get

A spinal cord stimulator (SCS) is an implanted device that sends mild electrical pulses to the spinal cord to dampen chronic pain. For some people it is genuinely life-changing. For others it does little. And the honest truth — the one you rarely hear in a sales pitch — is that the evidence is contested, the strongest trials were not done in people with spinal cord injury, and actually getting one approved and implanted can be a months-long fight. This page lays all of that out, with links to the evidence so you can check it yourself.

The short, honest version

• It's an established therapy with real but debated evidence. SCS has been FDA-cleared and used for chronic pain since the 1980s, and several randomized trials support it for specific conditions. But the highest-quality placebo-controlled studies have been underwhelming, and a 2023 Cochrane review concluded the benefit over a placebo may be small and uncertain. Both things are true at once.
• The best evidence is not about SCI pain. The landmark trials studied failed back surgery, leg/back pain, complex regional pain syndrome (CRPS), and diabetic neuropathy — not the central, below-level neuropathic pain most people with SCI have. Evidence specific to SCI is limited to small studies and case reports.
• A trial comes first. Before any permanent implant, you wear an external stimulator for about a week to see if it actually helps. Roughly 50% relief is the usual bar to proceed.
• Access is the hard part. A required psychological evaluation, a documented history of failed conservative treatment, insurance prior authorization (and frequent denials and appeals), and a shortage of implanters experienced with SCI central pain all stack up. If it has felt unreasonably hard, it's not just you.

What a spinal cord stimulator actually is & how it works

An SCS system has three parts: thin leads (wires with electrodes) placed in the epidural space just outside the spinal cord, an implanted pulse generator (a battery/computer, like a pacemaker for pain) placed under the skin of the buttock or flank, and a remote/app to control it. The electrodes deliver pulses to the dorsal columns of the cord, changing how pain signals are processed before they reach the brain.

The traditional approach ("tonic" stimulation) replaces the feeling of pain with a gentle tingling called paresthesia — which means the tingling has to cover the area that hurts. Newer approaches (high-frequency 10 kHz, burst, closed-loop) aim to relieve pain without any tingling at all. Which matters a lot after SCI, as you'll see below.

Crucially, it is a two-step process: a trial first (temporary leads, external battery, worn for ~5–7 days), and only if that clearly helps do you proceed to a permanent implant. The trial is your single best predictor of benefit — and your best protection against a device that won't help you.

The evidence it works

SCS is not fringe. It is recommended by major guideline bodies for specific conditions, and several randomized controlled trials (RCTs) support it:

• Failed back surgery syndrome (FBSS). The PROCESS RCT (Kumar, 2007) and North (2005) found SCS reduced leg pain better than repeat surgery or conventional medical management for persistent pain after spine surgery. This is the foundation of most coverage.
• Complex regional pain syndrome (CRPS). The Kemler RCTs (2000, 2004) showed benefit, and dorsal root ganglion (DRG) stimulation later outperformed traditional SCS for focal CRPS.
• High-frequency 10 kHz. The SENZA-RCT found Nevro's paresthesia-free 10 kHz therapy superior to traditional SCS for back and leg pain — the first head-to-head win over the older approach (Senza System review).
• Closed-loop stimulation. The double-blind EVOKE RCT (134 patients) showed Saluda's ECAP-controlled closed-loop SCS beat open-loop stimulation and held up over years — and it was the first SCS system approved by the FDA on the strength of a double-blind RCT (EVOKE summary).
• Painful diabetic neuropathy. 10 kHz SCS earned a dedicated FDA indication after RCT evidence of large pain reductions — showing the therapy works for some neuropathic (nerve) pain, not just mechanical back pain.

The UK's NICE guidance (TA159) recommends SCS for adults with chronic pain of neuropathic origin lasting at least 6 months (rated ≥50 mm on a 0–100 scale) despite conventional treatment, and who get relief in a stimulation trial. That last clause — a successful trial — is doing a lot of work.

The evidence it doesn't — the honest controversy

Here is the part that responsible doctors will tell you and marketing will not. When SCS is tested against a credible placebo (a device that's implanted but turned off, or set sub-threshold, so neither the patient nor assessor knows), the advantage shrinks — sometimes to nothing.

• A 2023 Cochrane review of SCS for low back pain (Traeger et al.) concluded that SCS probably provides little to no benefit over placebo, and that the data don't support its long-term use for low back pain (Cochrane CD014789).
• A placebo-controlled crossover RCT in JAMA (Hara, 2022) found that burst SCS produced no statistically significant difference in disability versus placebo (device off) in patients with chronic radiating pain after back surgery — a result that held at 6 months (JAMA, Hara 2022).

These studies set off a genuine fight in the field. Neuromodulation specialists published detailed rebuttals arguing the Cochrane review and the JAMA trial had methodological flaws that understated SCS's real-world benefit (critique, Pain Medicine; critique, Pain Practice). Critics of SCS counter that the rebuttals come largely from people and companies with a financial stake. You should know that this debate exists and is unresolved.

The fair takeaway: SCS clearly helps some people a lot, but on average the effect is more modest and more uncertain than the brochures suggest — which is exactly why the trial-before-implant step is so important.

The safety record & the public debate

Beyond whether it works, there is an active public argument about how safe SCS is and how well it is regulated. A 2018 Associated Press investigation found the FDA had received more than 80,000 injury reports tied to spinal cord stimulators over a decade — part of more than 220,000 adverse-event reports since 2004, including reports associated with over 900 deaths — making SCS one of the most-complained-about device categories the agency tracks (AP / NBC News). The watchdog group Public Citizen has separately argued the FDA's oversight of these implants has endangered patients (Public Citizen).

The complication numbers are real and worth knowing before you commit: published estimates put the overall complication rate around 30–40%, and lead problems, infection, or loss of benefit drive device-removal (explant) rates of roughly 6–9% per year, with some long-term series reporting higher (predictors of early removal). Most problems are mechanical (lead migration, revision surgery) rather than catastrophic — but they are common enough to belong in your decision.

None of this means the answer is automatically no. Many people keep their device for years and are glad they did. It means going in clear-eyed, choosing an experienced implanter, and treating the trial as the real decision point.

The SCI-specific reality (read this part twice)

Almost everything above was studied in people without spinal cord injury — mostly failed back surgery and limb pain. That matters because SCI neuropathic pain is different, and the device has to work across a damaged cord.

• At-level vs. below-level pain. Pain right around the injury level ("at-level") tends to respond better to SCS than the diffuse, central below-level pain many people describe as burning everywhere under the injury. Below-level central pain is the hardest type to treat with anything, SCS included.
• The SCS-specific SCI evidence is thin. There has never been a randomized controlled trial of SCS for SCI pain. A dedicated review of SCS for central neuropathic pain after SCI — and a systematic review of 69 such patients — rate the evidence low quality (SCS for central pain after SCI, review). A 2024 single-center case series found SCS helped mainly the patients who had preserved motor and sensory function (case series, 2024) — yet there are also reports of genuine success for below-level pain even in complete paraplegia (case report, 2017). For chronic neuropathic pain broadly, a 2023 meta-analysis of SCS found benefit in selected patients (SCS meta-analysis, 2023).
• The paresthesia problem. Traditional SCS works by putting a tingling sensation over the painful area. If you have reduced or absent sensation below your injury, it can be hard or impossible to feel — and therefore to steer — that tingling where it needs to go. This is one reason paresthesia-free options (10 kHz, burst, closed-loop) are often more interesting after SCI, and worth asking about specifically.
• Practical SCI considerations. Worth discussing with your team: autonomic dysreflexia risk during the trial and implant, skin/pressure-injury risk over the implant site if you sit on it, and MRI compatibility of the specific system (most modern devices are MRI-conditional, but confirm).

Therapy types (waveforms) — and why they matter for choosing

"Spinal cord stimulator" isn't one thing. Modern systems offer different stimulation styles, and the differences are a big part of what separates the companies below.

Every major company that makes spinal cord stimulators

Four companies — Medtronic, Abbott, Boston Scientific and Nevro — control roughly three-quarters of the market, with Saluda, Biotronik and Nalu as the notable challengers. Ownership is consolidating fast (two acquisitions closed or were announced in 2025 alone), so confirm current status with your implanter. Here is each maker, how long it has been in the SCS business, the device generations it has shipped, what makes it different, and an official link.

Medtronic — the original

Minneapolis, USA · making spinal cord stimulators since 1984 (the longest track record in the field).

Strengths: the deepest clinical and support infrastructure, closed-loop now in the lineup, and both rechargeable and recharge-free options. Trade-offs: a very large company; its closed-loop is newer than Saluda's, with less long-term comparative data. → Official site

Abbott (formerly St. Jude Medical)

Plano, USA · entered SCS through its January 2017 acquisition of St. Jude Medical, whose neuromodulation roots run to Advanced Neuromodulation Systems.

Strengths: the distinctive BurstDR waveform and a genuine DRG option for focal pain. Trade-offs: DRG implantation needs extra operator skill; DRG is less suited to diffuse below-level SCI pain. → Official site · St. Jude acquisition

Boston Scientific

Marlborough, USA · making SCS since 2004, when it launched the world's first rechargeable system.

Strengths: multi-waveform flexibility (mix therapies to find what works) and directional leads. Trade-offs: more options can mean more programming complexity. → Official site

Nevro

Redwood City, USA · founded 2006; pioneered paresthesia-free 10 kHz therapy. Acquired by Globus Medical in April 2025.

Strengths: the strongest brand in paresthesia-free 10 kHz, with real RCT data and a diabetic-neuropathy indication. Trade-offs: 10 kHz uses more energy (more recharging); some studies report higher explant rates; single-paradigm focus. → Official site

Saluda Medical

Founded 2011 (Australia/USA) · the closed-loop specialist.

Strengths: true real-time closed-loop control (helpful when transfers and position constantly change your dose), with durable RCT data. Trade-offs: newer and smaller than the big four; SCI-specific data, like everyone's, is limited. → Official site

Biotronik

Berlin, Germany · a cardiac-device veteran that entered US SCS in 2023.

Strengths: built-in remote monitoring and a deep engineering heritage from implantable cardiac devices. Trade-offs: the newest US entrant, so its real-world SCS track record is still short. → Official site · FDA approval

Nalu Medical

Carlsbad, USA · a micro-implant maker (announced October 2025 as a Boston Scientific acquisition).

Strengths: a very small implant with no internal battery to replace. Trade-offs: you wear the external disc during therapy; smaller track record, now being absorbed into Boston Scientific. → Official site

A note on completeness: several smaller and international players exist (for example Mainstay Medical's ReActiv8, which retrains back muscles rather than masking nerve pain and is aimed at mechanical low-back pain, not central SCI pain). For SCI neuropathic pain, the systems above are the ones you're most likely to be offered in the US.

Why it's so hard to get one

If pursuing an SCS has felt like pushing a boulder uphill, that's a normal experience — and after SCI it's harder than average. The barriers stack:

• A long list of prerequisites. Insurers and surgeons typically require months of documented failed conservative care (medications, physical therapy, injections), no untreated depression or substance-use disorder, and a pre-surgical psychological evaluation/clearance before they'll even authorize a trial (why the psych eval is required).
• Prior authorization and denials. Coverage runs through payer medical policies with strict criteria, and denials are common — followed by appeals, peer-to-peer reviews, and sometimes external review. The American Medical Association has flagged how prior authorization for non-opioid pain care like SCS prolongs patient suffering (AMA; example payer policy: UnitedHealthcare SCS policy).
• You're off the well-worn path. The approved indications and the strongest evidence are FBSS, CRPS and diabetic neuropathy. SCI central pain isn't one of the headline indications, so both insurers and many implanters are more cautious — the documentation burden is heavier and "medical necessity" is harder to argue.
• Few implanters specialize in SCI pain. SCS is implanted mostly by interventional pain physicians (and some neurosurgeons) whose typical patients are degenerative-spine and FBSS cases. Far fewer have deep experience with below-level central SCI pain — and outcomes are better with higher-volume, more experienced implanters, so finding the right one matters.
• The trial is a real gate. Even once approved, you must get meaningful relief during the ~1-week trial to proceed. For diffuse below-level pain that can be a genuine hurdle — and a "failed" trial, while disappointing, has just saved you a permanent implant that wouldn't have helped.
• And it may be getting harder. Beginning January 2026, Medicare is piloting a program ("WISeR") in six states — Arizona, New Jersey, Ohio, Oklahoma, Texas and Washington — that uses artificial intelligence to help screen prior-authorization for services including spinal cord stimulators, which patient advocates worry adds another layer of potential denial (Pain News Network).

Finding a doctor & improving your odds

• Start at a high-volume neuromodulation center, ideally one attached to an SCI program or academic medical center, rather than a general pain clinic. Experience with SCI central pain is the thing you're shopping for. Manufacturer and specialty locators can help you find implanters: Neuromodec SCS locator, Abbott clinic locator.
• Build the paper trail early. A clean record of failed medications and therapies, and a skin/shoulder or function history that shows real impact, strengthens the medical-necessity case your doctor submits.
• Do the psychological evaluation — it's standard, not an accusation, and a clean clearance removes a common denial reason.
• Ask specifically about paresthesia-free options (10 kHz, burst, closed-loop) given any sensory loss, and about which device and waveform the implanter thinks fits SCI central pain.
• Insist on a trial, and judge it honestly. Aim for clearly livable relief, not just a number — track sleep, activity and mood during the week, not only pain scores.
• If denied, appeal — denials are frequently overturned. Ask your doctor's office for a peer-to-peer review and, if needed, an independent external review. Equipment and benefits help is in our Benefits section, and the medication side of SCI pain is covered in Pain & Nerve Pain After SCI.

Questions to bring to a pain specialist

• Given that my pain is below-level / central (or at-level), what does the evidence say about my odds specifically — and which waveform fits best?
• How many SCS trials and implants do you do a year, and how many in people with spinal cord injury?
• Which device and why — and how do paresthesia-free options compare for my sensory loss?
• What exactly defines a "successful" trial for me, and what happens if it's borderline?
• Is the system full-body MRI-conditional, and what are the implant-site, autonomic-dysreflexia, and skin considerations for someone who sits all day?
• What are the realistic complication and explant rates, and what's the plan if benefit fades over time?

Sources & further reading

These summarize clinical guidelines, peer-reviewed research, regulatory records and manufacturer information in plain language. Follow the links for full detail, and bring anything useful to your care team.

1. NICE TA159 — Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin — nice.org.uk/guidance/ta159
2. Traeger AC et al. Spinal cord stimulation for low back pain — Cochrane Review, 2023 — Cochrane CD014789
3. Hara S et al. Spinal Cord Burst Stimulation vs Placebo Stimulation — JAMA, 2022 — JAMA · 6-month follow-up
4. Critiques of the placebo-controlled evidence — Pain Medicine · Pain Practice
5. SCS for central neuropathic pain after SCI — review (J Pain Research) — Dovepress · single-center case series (2024) — PubMed
6. SCS for chronic neuropathic pain — contemporary meta-analysis, 2023 — PubMed
7. SCS for below-level SCI pain in complete paraplegia (case report) — Spinal Cord Series & Cases, 2017 — Nature
8. Senza/HF10 (10 kHz) review — PubMed; Saluda EVOKE closed-loop trial — Neuromodec
9. Prior authorization & coverage — AMA · example payer policy
10. Manufacturers — Medtronic · Abbott · Boston Scientific · Nevro · Saluda · Biotronik · Nalu

Further reading & patient voices

The published trials don't capture everything patients live through. These outside perspectives — critical and optimistic — are worth your time:

• "Spinal-cord stimulators help some patients, injure others" — the Associated Press investigation (via NBC News).
• Public Citizen — watchdog critique of FDA oversight of SCS.
• Pain News Network — ongoing patient-focused reporting on SCS coverage and outcomes.
• Clinician explainers (the optimistic case): UCLA Health · HSS · AANS · Mayo Clinic patient story.

SCI.help articles are information, not medical advice. The SCS evidence base is genuinely contested and individual results vary widely — decisions about a trial or implant should be made with a qualified pain specialist who knows your full situation.